Reckitt buys Paras for $726 million

As the year draws to a close, private-equity firm Actis orchestrates the sale of its portfolio company Paras Pharmaceuticals in India to Reckitt Benckiser for $726 million.

Reckitt Benckiser has bought Paras Pharmaceuticals for Rs32.6 billion $726 million from its shareholders, which include the founding family, the Patels, and private-equity firms Actis and Sequoia. The deal captures the dual trends of consolidation in the consumer space in Asia and private-equity firms exiting investments, which have characterised this year.

Paras is a privately owned Indian company with a portfolio of leading over-the-counter health and personal care brands in India, including Moov, a topical analgesic pain ointment ...

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition

CONFERENCES